Investigational drug · Phase 2
APG777
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "APG777"
First trial start
2024
Apr 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "APG777", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "APG777" as an intervention, largest first.
- A Study Evaluating APG777 in Atopic DermatitisPivotal-lookingActive, not recruiting
Apogee Therapeutics, Inc.Industry
NCT06395948 · 470 participants · Start Apr 29, 2024 · Primary completion Nov 2026
Drug: APG777; Placebo · For: Atopic Dermatitis
Sites: Fountain Valley, California; Los Angeles, California; San Diego, California · 94 sites in all
Apogee Therapeutics, Inc.Industry
NCT07003425 · 350 participants (planned) · Start May 14, 2025 · Primary completion Dec 2029
Drug: APG777; APG777 and 1 more · For: Atopic Dermatitis
Sites: Fountain Valley, California; Los Angeles, California; Coral Gables, Florida · 80 sites in all
- An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisActive, not recruiting
Apogee Therapeutics, Inc.Industry
NCT07027527 · 86 participants · Start Jun 4, 2025 · Primary completion Aug 29, 2026
Drug: APG777; APG990 and 1 more · For: Atopic Dermatitis
Sites: Darlinghurst, Australia; Kogarah, Australia; Westmead, Australia · 20 sites in all
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaActive, not recruiting
Apogee Therapeutics, Inc.Industry
NCT06920901 · 31 participants · Start Mar 27, 2025 · Primary completion Sep 17, 2026
Drug: APG777; Placebo · For: Asthma
Sites: La Jolla, California; Long Beach, California; San Jose, California · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A First-in-Human, Single- and Multiple-Dose Study of APG777, a Half-Life-Extended Anti-IL-13 Monoclonal Antibody, in Healthy Volunteers.
Lim XQ, Winter E, Nograles K, et al. · Clin Transl Sci 2025
- In vitro potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb.
Zhu E, Prentice H, Oh J, et al. · J Allergy Clin Immunol Glob 2025
- Preclinical Safety of APG777, A Novel Extended Half-Life Anti-Interleukin-13 Monoclonal Antibody, in Cynomolgus Monkeys.
Rubio D, Zhu E, Thurston A, et al. · Int J Toxicol 2025
- Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis.
Yilmaz O, Torres T · Dermatol Ther (Heidelb) 2024
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.